Fusion constructs and methods of using thereof

Inventors

Sabzevari, Helen • METENOU, Simon • Chen, ChangHung • SHAH, Rutul R.

Assignees

Precigen Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12703747-B2

Patent

Publication Date

2026-08-11

Expiration Date


Abstract

Provided herein is a composition comprising a fusion protein or a fragment or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a TGF-β trap. Provided herein is a composition comprising a fusion protein or a fragment thereof or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a ADA2 polypeptide. Also provided herein are methods of using the composition in treating cancer.

Core Innovation

The disclosure describes a method of treating colorectal cancer, head and neck cancer, or ovarian cancer by administering a therapeutically effective amount of a fusion protein. The fusion protein comprises an antibody, antigen-binding fragment, or variant that specifically binds programmed cell death protein-1 (PD-1), joined to a transforming growth factor beta (TGF-̂-trap) cytokine trap via a peptide linker. Disclosed cytokine traps include TGF̂-trapRII extracellular domains, anti-TGF-̂-trap antibodies, or inhibitory peptides.

The approach combines PD-1 pathway blockade with TGF-̂-trap neutralization to counter tumor immune suppression. Evaluated anti-PD-1-TGF-̂-trapRII fusions mediate PD-1/PD-L1 blockade and neutralize TGF-̂-trap1, TGF-̂-trap2, and TGF-̂-trap3 signaling while enhancing stimulated PBMC proliferation and IFN-̂-trap production. Evaluations further report increased CD8:Treg ratios, tumor-growth inhibition, improved survival, and enhanced CAR-T-cell-mediated tumor-cell killing.

Claims Coverage

The claims recite one independent claim directed to a cancer-treatment method, defining one inventive feature.

Treatment of specified cancers with a PD-1-binding antibody and TGF-̂-trap cytokine trap fusion protein

The independent claim covers administering a therapeutically effective amount of a fusion protein to treat colorectal cancer, head and neck cancer, or ovarian cancer. The fusion protein comprises an antibody, antigen-binding fragment, or variant specifically binding PD-1 connected by a peptide linker to a TGF-̂-trap cytokine trap, with sequence combinations specified in the claim.

The independent claim centers on treating colorectal, head and neck, or ovarian cancer using a sequence-defined PD-1-binding antibody component and a TGF-̂-trap cytokine trap connected by a peptide linker.

Stated Advantages

Combining PD-1 pathway blockade with TGF-̂-trap neutralization counters tumor immune suppression by blocking the PD-1/PD-L1 interaction and neutralizing TGF-̂-trap1, TGF-̂-trap2, and TGF-̂-trap3 signaling.

The fusion protein demonstrates dose-dependent enhancement of stimulated PBMC proliferation, T-cell division, and increased IFN-̂-trap or cytokine production compared with anti-PD-1 alone or control treatments.

Tumor models demonstrate reduced tumor volume, tumor-growth inhibition, increased tumor-infiltrating lymphocytes or CD8:Treg ratios, and improved survival measures.

The fusion protein enhances CAR-T-cell-mediated tumor-cell response, killing, and lysis in combination assays.

Documented Applications

Treatment of colorectal cancer, head and neck cancer, or ovarian cancer using the claimed PD-1-binding antibody and TGF-̂-trap cytokine trap fusion protein.

Combination therapy with engineered effector T cells expressing an exogenous receptor, including chimeric antigen receptor (CAR) T cells directed to MUC16, CD33, CD19, BCMA, and PSMA, or T-cell receptors.

Administration of an alternative anti-PD-1-ADA2 fusion targeting extracellular adenosine.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.